Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper
Diana A. Gorog(University of Hertfordshire), Gregory Y.H. Lip(Medical University of Białystok), José Luis Ferreiro(Institut d'Investigació Biomédica de Bellvitge), Francisco Marı́n(Instituto Murciano de Investigación Biosanitaria), Stavros V. Konstantinidis(Johannes Gutenberg University Mainz), Laurent Fauchier(Université de Tours), Ying X. Gue(University of Liverpool), Andrea Rubboli, Hung‐Fat Tse(University of Hong Kong), Tatjana Potpara(University of Belgrade), Vanessa Roldán(Hospital Universitario Virgen de la Arrixaca), Kurt Huber(Sigmund Freud Privatuniversität Wien), Dirk Sibbing(Ludwig-Maximilians-Universität München), Gemma Vilahur(Instituto de Salud Carlos III), Tze‐Fan Chao(National Yang Ming Chiao Tung University), Jonas Oldgren(Uppsala University), Deirdre A. Lane(University of Liverpool)
Cited by 113
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k